Amphotropic retroviruses with a hybrid long terminal repeat as a tool for gene therapy of cystic fibrosis.
Biochem Biophys Res Commun
; 187(1): 187-94, 1992 Aug 31.
Article
in En
| MEDLINE
| ID: mdl-1325788
We have made two retroviral vectors encoding the bacterial beta-galactosidase (lacZ) as a marker gene and a long terminal repeat (LTR) containing an enhancer of the polyoma F101 virus [symbol: see text]. One vector, [symbol: see text], can be used as a test vector in grafting, lineage analysis and gene therapy studies. The other, [symbol: see text] carries an additional unique cloning site in which a gene of interest can be cloned. Titration experiments showed that in human epithelial cell lines, [symbol: see text] produces a transcriptionally active integration more often than the commonly used BAG vector with the wild type LTR. Human epithelial cells in primary culture could be successfully infected. Our data suggest that gene therapy protocols requiring infection in situ, such as in the case of cystic fibrosis, will be hampered by the relatively low local titres that can be achieved at present.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Repetitive Sequences, Nucleic Acid
/
Genetic Therapy
/
Cystic Fibrosis
/
Genetic Vectors
/
Moloney murine leukemia virus
Type of study:
Guideline
Limits:
Humans
Language:
En
Journal:
Biochem Biophys Res Commun
Year:
1992
Document type:
Article
Affiliation country:
Netherlands
Country of publication:
United States